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Abstract
Background: Hypertension is one of the leading causes of cardiovascular disease (CVD). A range of
antihypertensive drugs exists, and their prices vary widely mainly due to patent rights. The objective of this study
was to explore the cost-effectiveness of different generic antihypertensive drugs as first, second and third choice
for primary prevention of cardiovascular disease.
Methods: We used the Norwegian Cardiovascular Disease model (NorCaD) to simulate the cardiovascular life of
patients from hypertension without symptoms until they were all dead or 100 years old. The risk of CVD events
and costs were based on recent Norwegian sources.
Results: In single-drug treatment, all antihypertensives are cost-effective compared to no drug treatment. In the
base-case analysis, the first, second and third choice of antihypertensive were calcium channel blocker, thiazide and
angiotensin-converting enzyme inhibitor. However the sensitivity and scenario analyses indicated considerable
uncertainty in that angiotensin receptor blockers as well as, angiotensin-converting enzyme inhibitors, beta
blockers and thiazides could be the most cost-effective antihypertensive drugs.
Conclusions: Generic antihypertensives are cost-effective in a wide range of risk groups. There is considerable
uncertainty, however, regarding which drug is the most cost-effective.
Background
Hypertension is a major risk factor for cardiovascular dis-
ease (CVD) such as acute myocardial infarction (AMI),
stroke, heart failure and death. WHO has estimated that
hypertension alone accounts for 4.4% of all disability
adjusted life years that are lost [1]. An array of rando-
mized controlled trials (RCTs) has demonstrated that
antihypertensive drugs can reduce the risk of CVD. This
is the case for thiazides, beta blockers, calcium channel
blockers (CCB), angiotensin receptor blockers (ARB) and
angiotensin-converting-enzyme inhibitors (ACE) [2].
Still, there is uncertainty and even controversy related to
the intervention thresholds and the choice of first-line
drug and “add-on” drugs. The controversy is partly
related to the price of the different drugs, and partly to
disagreements about how the available evidence on effec-
tiveness, and side-effects of the various drugs should be
interpreted [3,4].
The prices of the different antihypertensives vary, and
price alone is only one factor which should be taken into
account when considering which drugs that should be
reimbursed. Several countries, including Norway, have
chosen to use economic evaluation (cost-effectiveness
analysis) for reimbursement decisions and development
of guidelines. This implies that health authorities issue
guidelines for choice of drugs and may even deny reim-
bursement of drugs that are too expensive in relation to
the effectiveness. For example, the National Institute of
Health and Clinical Excellence (NICE) in the UK may
recommend against reimbursement of drugs when the
cost per quality adjusted life year (QALY) exceeds
£30,000 [5]. The argument for such thresholds is simply
that if the costs of gaining a life year are beyond £30,000,
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resources may generate more health if they were spent
elsewhere in the health care system. Cost-effectiveness
analyses have been widely used for some types of thera-
pies such as cholesterol lowering drugs. For antihyperten-
sive therapies, however, relatively few studies have been
published, especially during the last five years [6]. It is
therefore a paucity of updated studies of the cost-effec-
tiveness of such therapies.
A recent project funded by Norwegian health authorities
offered a basis for developing guidelines for choice of anti-
hypertensive drugs. The project first involved a compre-
hensive literature review and subsequent meta-analyses
[2], and secondly, the development of a simulation model
(Norwegian Cardiovascular Disease model (NorCaD)) [7]
for economic evaluation. The aim of this study was to
explore the life-time cost-effectiveness of various generic
antihypertensive drugs in order to propose first-line ther-
apy of hypertension and later add-ons for patients who
need more than one drug. The scope of the project was
restricted to primary prevention of CVD events. We
assumed that patients first are offered dietary and other
life style advice in order to achieve an acceptable blood
pressure and that drugs are only prescribed when treat-
ment goals are not reached with non-pharmacologic mea-
sures. We chose to use life years gained as the measure of
health benefit because relatively few clinical trials report
quality of life endpoints. We adopted a health care
perspective which means that the analyses capture all
costs that are incurred to the health care system.
Methods
Decision-analytic model
We used TreeAge Pro® to develop a decision-analytic
cardiovascular model which follows patients without
prior cardiovascular incidents from the asymptomatic
stage through their cardiovascular life to death [7].
Because CVD involves various types of disease events
and health states, we chose to build a Markov model that
follows individuals with different baseline characteristics
(blood pressure, cholesterol level, etc.) until they all are
dead or become 100 years (Figure 1). A full description
of the model is available [7].
In the model, individuals start as “healthy” or “disease-
free”, i.e. without any prior cardiovascular event or symp-
toms. Disease-free individuals are subject to various
primary CVD events: Acute myocardial infarction (AMI),
stroke, heart failure, angina, death from cardiovascular dis-
ease. In addition, all individuals are at risk of death from
other causes. The risks of these events were based on data
from Norwegian registries and a Norwegian cohort study
[8-10]. That is, we assumed that individuals follow the age-
and sex specific incidence rates for the Norwegian popula-
tion. After the first CVD event, patients either move
directly into a CVD health state, or they may experience a
Figure 1 Model structure.
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secondary CVD event (e.g. reinfarction) and then move
into a CVD health state. The NorCaD model consists of
nine different health states: disease-free, heart failure, mod-
erate stroke sequelae, severe stroke sequelae, post myocar-
dial infarction, post angina, post stroke without sequelae,
dead from cardiovascular causes and dead from other
causes. Being alive in these health states, patients are at
risk of worsening or of having secondary cardiovascular
events (Figure 1). Figure 1 is a simplification as post MI,
post angina and post stroke without sequelae are repre-
sented with one state “Asymptomatic CVD” (post CVD
event). Moderate and severe sequelae are represented by
stroke sequelae.
Patients who experience a secondary event are
assumed to be in the health state which is worst. Hence
if a patient with stroke sequelae experiences a myocar-
dial infarction, costs and risks of an AMI is added, but
thereafter the patient again has the risks and costs asso-
ciated with the stroke sequelae and not those related to
having asymptomatic CVD.
Probabilities of events
The model was calibrated to predict Norwegian CVD
specific mortality rates (for further details see technical
report [7]) and we used life years gained as the measure
of benefit in the analysis. In line with Norwegian guide-
lines for socioeconomic analyses, we used a 4% discount
rate for both health outcomes and costs. In practice this
implies that costs and health outcomes is valued 4%
lower for each year. This approach of discounting is com-
mon within economic analyses to numerically describe
the fact that most people rather would have money or
good health today than in their future.
Most data on the probability of secondary events were
based on international registries (EuroHeart [11-15] &
GRACE [16,17], see also [7]), but RCT data were used
when registry data were unavailable (see Tables 1 and 2).
The risk of secondary events were dependent on time
since primary event and age [7].
Effectiveness
The effectiveness of antihypertensive drugs was modelled
by reducing the risk of primary CVD events based on
meta-analyses from a recent systematic review [2]. This
systematic review followed common standards for sys-
tematic reviews according to the Norwegian Knowledge
Centre for the Health Services, which is the centre respon-
sible for Cochrane reviews and health technology assess-
ments in Norway. The reason for choosing this review was
that this is a recent review which is thoroughly performed
by a qualified group of experts in both cardiology, evi-
dence based medicine and pharmaceuticals. All searches
for literature were performed by experienced librarians
and the reviewing process was performed according to
international standards. The systematic review included 33
trials with in total 210,394 patients comparing antihyper-
tensive drugs against each other or against placebo.
For all analyses, we followed patients until all were
100 years old or dead.
We did not include any impact of antihypertensives on
the risk of heart failure and angina as primary events in
the base case analyses because these outcomes are
“softer” and more difficult to measure uniformly in trials.
We did, however, conduct scenario analyses with these
two outcomes included. This strategy is in accordance
with the reporting of the meta-analysis [2] upon which
this study was based. There, angina and heart failure
were classified as “secondary outcomes”.
The ALLHAT trial weighted heavily in the meta-analysis
of ACE inhibitors. This trial had a considerable proportion
of African American patients, and they may respond less
to ACE treatment than Caucasians [38]. The ACE meta-
analysis was therefore conducted both with and without
the African American patients (Table 3) [38]. In our base
case analyses, we used the meta-analyses where African
Americans were excluded from the ALLHAT study, while
these were included in our scenario analyses. For all other
meta-analyses which our efficacy data were based on, we
refer to the mentioned HTA report [2].
When estimating the effectiveness of combinations of
two or three drugs we assumed a multiplicative interac-
tion between the drugs, as has been done in previous
similar analyses [39,40]. If for example the relative risk
reduction was 10% (relative risk 0.9) for one drug and
20% (relative risk 0.8) for the other, we assumed the
combined effect represented 28% relative risk reduction
(1-0.8*0.9 = 0.28).
Costs
The costs were estimated for primary events, secondary
events and health states separately. Data on the quantity
of use of health care were estimated from published stu-
dies, treatment guidelines and expert opinions. Data on
unit costs were based on price lists from the Norwegian
Medicines Agency (drugs), Norwegian fee schedules
(doctors and outpatient clinic visits) and DRG price lists
from 2011 (in-hospital care) [41-44]. Unit costs and
resource use were combined into cost parameters for
each event and health state (Table 4). We chose the least
expensive in each group of antihypertensive drugs with
doses similar to those of the relevant trials. We measured
all costs in 2011 Norwegian kroner (NOK) and expressed
them in Euro (€1.00 = NOK8.01).
We undertook analyses for different patient groups
according to age, sex and CVD risk factors. First, we ran
the model for each patient group without treatment. Sub-
sequently, we ran it with various single, double and triple
drug therapies. For each drug regimen we calculated the
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Table 1 Risk of secondary events during the first year after a primary event
Primary event Secondary event Probability of secondary event Comment
Value Low High Time
Angina Cardiovascular death (men) 0.0108 0.0060 0.0156 One year Daly et.al. (EuroHeart) [11]
Angina Cardiovascular death (women) 0.0134 0.0071 0.0197 One year Based on Daly et.al. (EuroHeart) [11]
Angina AMI (men) 0.0153 0.0096 0.0211 One year Based on Daly et.al. (EuroHeart) [11]
Angina AMI (women) 0.0173 0.0101 0.0245 One year Based on Daly et.al. (EuroHeart) [11]
Angina Stroke (men) 0.0119 0.0069 0.0170 One year Based on Daly et.al. (EuroHeart) [11]
Angina Stroke (women) 0.0110 0.0053 0.0168 One year Based on Daly et.al. (EuroHeart) [11]
Angina Heart failure (men) 0.0153 0.0096 0.0211 One year Based on Daly et.al. (EuroHeart) [11]
Angina Heart failure (women) 0.0181 0.0108 0.0254 One year Based on Daly et.al. (EuroHeart) [11]
AMI Death (30-59 years) 0.04 0.074 0.106 One year Swedish official data [18]
AMI Death (60-69 years) 0.09 0.074 0.106 One year Swedish official data [18]
AMI Death (70-79 years) 0.20 0.074 0.106 One year Swedish official data [18]
AMI Death (80 years or more) 0.38 0.074 0.106 One year Swedish official data [18]
Non-Stemi Angina* 0.090 0.074 0.106 One year ICTUS [19]
Non-Stemi Heart failure 0.246 0.235 0.256 In-hospital Fox, GRACE [16]
Non-Stemi Reinfarction 0.014 0.011 0.017 In-
hospital**
Hasdai, EuroHeart 1 [12]
Non-Stemi Stroke 0.018 0.015 0.020 6
months***
Budaj, GRACE [17]
Non-Stemi Stroke 0.009 0.007 0.011 In-
hospital***
Budaj, GRACE [17]
STEMI Angina* 0.114 0.083 0.145 One year Zijlstra 1999 [20]
STEMI Heart failure 0.288 0.277 0.298 In-hospital Fox, GRACE [16]
STEMI Reinfarction 0.027 0.022 0.032 In-
hospital**
Hasdai, EuroHeart 1 [12]
STEMI Stroke 0.021 0.018 0.023 6
months***
Budaj, GRACE [17]
STEMI Stroke 0.013 0.011 0.015 In-
hospital***
Budaj, GRACE [17]
Reinfarction Stroke Assumed to be the same as after STEMI/non-STEMI
Reinfarction Angina* Assumed to be the same as after STEMI/non-STEMI
Reinfarction Death* 0.242 0.135 0.349 30 days Andersen, DANAMI-2 [21]
Reinfarction Heart failure Assumed to be the same as after STEMI/non-STEMI
Secondary heart
failure
A heart failure llasts for 6-12
months
0.500 0.333 0.750 Expert opinion (SH)
Secondary heart
failure
Death 0.290 0.240 0.340 One year Based on EuroHeart 2 [13]
Primary heart
failure
Death (men) 0.173 0.132 0.213 One year Based on EuroHeart 2 [14]
Primary heart
failure
Death (women) 0.163 0.116 0.209 One year Based on EuroHeart 2 [14]
Stroke Death 0.338 0.315 0.361 One year Based on registry data Terent et.al. [22] and
Kammersgaard et.al. [23]
Stroke Moderate sequelae 0.072 0.060 0.084 One year Based on registry data, Riks-Stroke [24]
Stroke Severe sequelae 0.169 0.158 0.180 One year Based on registry data, Riks-Stroke [24]
*Adjusted because data stems from RCTs
** In-hospital probabilities are assumed to be half of one-year-probabilities (1/3 - 1 in sensitivity analyses)
***Here exist both in-hospital and 6 month data (see formula under 2.2)
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additional (incremental) lifetime cost and additional life
expectancy.
Sensitivity analyses
The NorCaD model is based on approximately 300 para-
meters. Parameters with uncertainty were modelled as
distributions rather than point values. It should be noted
that uncertainty in this context means “parameter uncer-
tainty” or “second order uncertainty” and not variability or
heterogeneity across patients [45]. All probabilities and
adherence rates were incorporated as beta distributions
because they are restricted to values between 0 and 1 [46].
Table 2 Risk of new CVD events more than one year after first CVD event relative to healthy subjects
Health state Secondary event Probability of
later event
Comment
Value Low High
Post AMI AMI* 3.05 1.47 4,60 DANAMI-2 [25]
Post AMI Angina* 21.7 15.8 27.6 Zijlstra [20]
Post AMI Dying (30-59 years)* 3.55 OPTIMAAL [26], DANAMI-2 [25], and RIKS-HIA [18]
Post AMI Dying (60-69 years)* 2.36 OPTIMAAL [26], DANAMI-2 [25], and RIKS-HIA [18]
Post AMI Dying (70 years or more)* 1.00 OPTIMAAL [26], DANAMI-2 [25], and RIKS-HIA [18]
Post AMI Stroke* 2.77 2.08 3.47 Zijlstra [20]
Post angina AMI (men) 3.88 2.24 5.60 OPTIMAAL [26]
Post angina AMI (women) 1.17 0.76 1.59 OPTIMAAL [26]
Post angina Angina* 11.32 8.30 14.29 Assumed to be half of the probability first year, SMM-report nr
5/2002 [27]
Post angina Death 1.23 0.82 1.65 Assumed to be half of the probability first year, SMM-report nr
5/2002 [27]
Post angina Stroke (men) 5,34 NOKC-report nr 8/2004 [28]
Post angina Stroke (women) 5,26 Based on meta-analyses from Nordmann [29] + HKS [9]
Post stroke AMI 3.51 1.78 5.33 Risks based on relationship between angina and well first year after
angina
Post stroke Death 4.91 3.86 5.97 Risks based on relationship between angina and well first year after
angina
Post stroke Stroke 2.82 1.81 3.48 van Wijk [30]
Heart failure dying 2nd year after HF
(women)
6.67 6.16 11.04 van Wijk [30] and SSB [31]
Heart failure dying 3rd year after HF
(women)
7.61 5.08 10.15 van Wijk [30]
Heart failure dying later years after HF
(women)
2.45 0.90 4.00 Rosolova, Euroheart 2 [14]
Heart failure dying 2nd year after HF (men) 5.05 3.24 6.86 Rosolova, Euroheart 2 [14]
Heart failure dying 3rd year after HF (men) 4.62 2.90 6.33 Rosolova, Euroheart 2 [14] and SSB [31]
Heart failure dying later years after HF (men) 2.13 0.96 3.31 Rosolova, Euroheart 2 [14]
Heart failure Stroke* 6.80 3.40 13.61 Rosolova, Euroheart 2 [14]
Heart failure Worsening of HF 9.58 9.04 10.13 Rosolova, Euroheart 2 [14] and SSB [31]
Heart failure AMI after HF (men) 1.5 0.6 3.8 Based on SAVE [32] and SOLVD [33]
Heart failure AMI after HF (women) 4.1 1.8 9.3 Cleland, Euroheart [15]
Moderate stroke
sequelae
AMI 4.41 3.32 5.28 Based on Mosterd et.al. [34]
Moderate stroke
sequelae
heart failure 2 1 4 Based on Mosterd et.al. [34]
Moderate stroke
sequelae
New stroke 4.30 3.92 4.62 Based on meta-regression from Touzé et.al. [35]
Moderate stroke
sequelae
Dying 2 1.5 2.5 Expert opinion (ISK)
Severe stroke sequelae Dying 3 2.25 3.75 Meta-analysis of Hillen [36] and Caro [37]
*Adjusted down in the model because the data stems from RCT’s
Wisløff et al. BMC Cardiovascular Disorders 2012, 12:26
http://www.biomedcentral.com/1471-2261/12/26
Page 5 of 12
Unit costs and quantifications of cost items were assumed
to follow gamma distributions because such data typically
are skewed with a long right tale. Relative risks were incor-
porated as log-normal distributions due to the properties
of the logarithm of relative risks. Monte Carlo simulation
of the model was run with 10,000 iterations.
Framework for priority setting
The result of an economic evaluation typically concludes
that one therapy, as compared to another, has an incre-
mental cost (IC) and an incremental effect (IE)(e.g. life
years gained). Traditionally, the final result of the analy-
sis has been expressed as an incremental cost-effective-
ness ratio (ICER):
ICER = IC/IE
In order to maximize health (e.g. life years) within a
given budget, decision makers ought to prioritize treat-
ments with the lowest ICER’s until the budget is
exploited. In practice, most health care programmes
have not been subject to economic analysis, and hence,
pragmatic thresholds for the ICER are chosen. We
assumed that this threshold (T) is €62,000 (≈NOK
500,000; €1 = NOK8.01) per life year gained as sug-
gested by the Norwegian Directorate of Health [47].
On some occasions, however, the simple rule based on
ranking ICER’s results in suboptimal priority setting. We
therefore based the choice of antihypertensive therapies
on the so called “incremental net health benefit” (INHB)
approach. The INHB has the following definition:
INHB = IE− IC/T
If for example a treatment on average generates 1.3
life years per patient, have lifetime costs of €31,000
(including off-sets from avoided events) and T is
€62,000, then INHB = 1.3-31,000/62,000 = 0.8. With
this formula, cost-effective strategies will have positive
INHB. If different strategies are compared to the same
baseline, the strategy with the highest INHB is regarded
as the most cost-effective. When choosing between
treatments, health outcome will be maximized by choos-
ing on the basis of INHB. If INHB is negative, the ther-
apy is not cost-effective and resources should be spent
elsewhere [45].
Results
The model was run for four different age groups of
women and men with average risk of CVD, that is fol-
lowing the national age- and sex-specific incidence rates
from the registries. Firstly, CCB was compared to pla-
cebo (Figure 2), in which case treatment was dominant
(less costly and higher effectiveness) in all age groups
(40, 50, 60 and 70 years old). The (discounted) increase
in life expectancy was similar for men and women, but
higher for older age groups. The difference in (dis-
counted) costs was also highest for the oldest age
groups, which implies that INHB was highest for 70
year olds (0.42 and 0.39 for women and men respec-
tively), and lower for the other age groups. All INHB’s
were positive based on a threshold for cost-effectiveness
of €62,000 per life year gained.
To explore which drug is the most cost-effective first
line antihypertensive treatment, we used head-to-head
trials comparing drugs with CCB (Table 5). These analyses
indicate that CCB may be the most cost-effective for all
age groups (both men and women).
Subsequently, we analyzed the choice of add-on
treatment for patients who do not reach the treatment
target. Here we compared CCB alone with any combi-
nation of two antihypertensive drugs. For all age
groups, all combinations were dominant compared to
CCB alone. The combination of CCB and thiazide
yielded the greater positive incremental net health ben-
efit, which indicates that this combination may be the
most cost-effective combination of two drugs (Table 6).
Table 3 Relative risks of outcomes according to type of
treatment (ACE inhibitor vs CCB and diuretics* vs ACE
inhibitor) and outcome (based on meta-analyses)
ACE inhibitor vs. CCB (all included)
Outcome RCTs Patients RR (random), 95% CI
Mortality (total) 2 22,503 1.05 [0.98 til 1.11]
AMI 2 22,503 0.97 [0.84 til 1.13]
Stroke 2 22,503 1.13 [0.97 til 1.32]
Heart failure 2 22,503 0.85 [0.78 til 0.94]
Angina 1 18,102 1.07 [0.99 til 1.17]
Diuretics vs. ACE inhibitor (all included)
Mortality (total) 3 31,249 1.00 [0.95 til 1.07]
AMI 2 30,392 1.01 [0.88 til 1.17]
Stroke 3 31,249 0.88 [0.80 til 0.98]
Heart failure 2 30,392 0.94 [0.71 til 1.24]
Angina 1 24,309 0.91 [0.85 til 0.98]
ACE inhibitor vs. CCB (african american excluded)
Mortality (total) 2 16,080 1.03 [0.96 til 1.11]
AMI 2 16,080 0.96 [0.85 til 1.08]
Stroke 2 16,080 1.04 [0.92 til 1.19]
Heart failure 2 16,080 0.86 [0.80 til 0.93]
Angina 1 11,679 1.05 [0.95 til 1.15]
Diuretics vs. ACE inhibitor (african american excluded)
Mortality (total) 3 22,670 1.04 [0.96 til 1.12]
AMI 2 21,813 1.02 [0.93 til 1.12]
Stroke 3 22,670 0.98 [0.86 til 1.12]
Heart failure 2 22,670 0.97 [0.90 til 1.05]
Angina 1 15,730 0.95 [0.87 til 1.04]
*In our analyses, we have used the meta-analysis results for diuretics for the
effect of thiazides
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Hence, thiazide may be the most cost-effective first
choice add-on treatment.
The subsequent analyses indicated that ACE inhibitor
may be the most cost-effective second add-on drug when
patients already use CCB and thiazide (Table 7). In this
analysis, we also included other combinations of three
drugs and none of these were more cost-effective than
the combination of thiazide, CCB and ACE-inhibitors in
any age group.
Sensitivity and scenarios
We performed probabilistic sensitivity analysis on the
comparison of single drugs for 70 year old men. These
analyses indicate substantial uncertainty with respect to
which drug is the most cost-effective (Figure 3). No sin-
gle drug was more than 50% likely to be the most cost-
effective antihypertensive, regardless of what society is
willing to pay for a life year gained. We also performed
probabilistic sensitivity analysis on the choice of combi-
nation treatment of two or three drugs in 70 year old
men (Figures 4 and 5). In Figure 5, there is a 72%
probability that thiazide, CCB and ACE inhibitors are
the most cost-effective combination of three drugs at a
WTP of €62,000.
When African Americans from the ALLHAT study were
included in meta-analyses, the conclusions were basically
the same as when they were not (results not shown).
When we included heart failure and angina in the
model, ARB was more likely than CCB to be the most
cost-effective first-line treatment for hypertension (36%
and 24% respectively)(data not shown). With angina and
heart failure included, the choice of first add-on treatment
was also more uncertain, even though a combination of
either CCB, ARB or diuretics seemed most likely. In ana-
lyses of the combination of three drugs; all combinations
seems almost equally likely of being the most cost-effective
alternative if this more comprehensive model is used
(results not shown).
Discussion
For 40, 50, 60 and 70 year old men and women, generic
CCB, thiazide, ACE inhibitor, ARB and beta blocker are
Table 4 Cost parameters (2011 Norwegian Kroner (NOK), €1.00 = NOK8.01)
Description Value (€)
Cost of developing angina and have treatment 15,242
Cost of being in the state post MI for a year 331
Cost of being in the state post stroke for a year 292
Cost of being in the state post angina for a year 292
Cost of dying a cardiac death in hospital 5,169
Short term costs of developing heart failure 1,346
Cost of worsening of heart failure 4,598
Cost of one year with heart failure 3,569
Cost of living in the health state moderate stroke sequelae 6,436
Costs of treating a non-ST-elevated myocardial infarction 22,674
Cost of being in the health state severe stroke sequelae (i.e. one year in nursing home) 99,875
Cost of reinfarction 3,713
Costs treating an ST-elevated MI 22,674
Costs of getting stroke 23,546
Cost of one unit DRG 4,615
Cost of GP visits when receiving statin treatment (first year) 185
Cost of GP visits when receiving statin treatment (later years) 94
Cost of GP visits when receiving thiazide treatment (first year) 195
Cost of GP visits when receiving thiazide treatment (later years) 97
Yearly cost of thiazide (hydrochlorothiazide 12.5 mg*) 20
Yearly cost of ACE inhibitor (enalapril 20 mg) 58
Yearly cost of calsium channel blocker (Amlodipin 5 mg*) 30
Yearly cost of ARB (losartan 100 mg**) 73
Yearly cost of beta blocker (atenolol 50 mg***) 35
*For hydrochlorothiazide and amlodipin we assumed half a pill each day
**For losartan we assumed half a pill the first 6 days
***For atenolol, we assumed two pills per day
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all cost-effective and even cost-saving antihypertensives,
even when two or all three are used in combination
when this is indicated. CCB seems to be the most cost-
effective alternative and consequently the first-line drug.
If patients do not reach the treatment targets on CCB,
thiazide is the most cost-effective add-on treatment.
The sensitivity analyses, however, indicate considerable
uncertainty in the ranking, and other factors such as
side effects may well dictate the choice in the clinical
setting.
The modelling showed lower incremental health bene-
fit in younger than in older age groups. This may seem
counterintuitive. To test this result, we performed vali-
dating analyses without discounting (Figure 2). From
these, we concluded that the reason for the counterin-
tuitive results is discounting. When the model was run
without discounting, the incremental benefits are greater
in younger age groups. Discounting decreases life years
gained more in younger than in older age groups.
Because benefits from antihypertensives in terms of life
years gained occur at a late stage in life, discounting
leads to lower incremental health benefit in the younger
compared to the older age groups.
We used a 4% discount rate throughout this study,
because this is currently recommended in Norwegian
guidelines. We are aware, however, of the ongoing dis-
cussion regarding whether costs and/or effect should be
discounted, and at what percentage [48,49]. If no dis-
counting were applied, the age effects would be reversed
in the sense that the ICERs would be more favourable for
the young than the older age groups (Figure 2). If only
costs were discounted, the difference in cost-effectiveness
between age groups would be relatively small (Figure 2).
The estimated life year gains from taking CCB for the
remainder of the lifetime compared to no antihypertensives
is close to 0.5 (undiscounted). This may seem to be a small
number when being 50 years old and expecting about 30
more years to live. Two points are worth mentioning, how-
ever. First, the 0.5 year is an average, and some patients
may gain much more while others have no benefit. Some
patients may die from other causes such as cancer or acci-
dents and have no benefit from the antihypertensive treat-
ment. Others may avoid a fatal stroke in their 60’s and live
until 80 because they started using antihypertensive drugs
in their 50’s. Second, 0.5 year is a considerable benefit in a
public health perspective.
Models may be constructed in several different ways,
and structural differences between them may in some
cases result in considerably different results and alter the
conclusions. Inclusion of heart failure and angina in the
model made the results much more uncertain because
the efficacy data are not consistent for these outcomes.
We have not identified other cost-effectiveness ana-
lyses of all these antihypertensives. However the UK
guidelines from 2011 [50], which are based on similar
efficacy documentation as our analyses, propose ACE
inhibitor, CCB or possibly a low-cost ARB as the first
choice. These guidelines also suggest that that a combi-
nation of CCB and either ARB or ACE inhibitor is the
recommended combination of two drugs. If three drugs
are to be combined, a thiazide-like diuretic is to be
combined with the two-drug combination. These
recommendations seem to fit well with our results.
Sex Age Expected remaining 
lifetime without 
treatment 
(undiscounted) 
Expected remaining 
lifetime without 
treatment (discounted) 
Life years gained  
(undiscounted) 
Life years gained  
(discounted) 
Incremental costs, 
€ (undiscounted) 
Incremental 
costs, € 
(discounted) 
ICER (discounted),  
€ / life year gained 
Incremental net 
health benefit 
(discounted), life 
year 
W
om
en
 40 43,4 20,3 0,46 0,08 -221 148 -47 203 -621 537 0,17 
50 33,9 18,1 0,46 0,11 -222 546 -70 173 -630 144 0,25 
60 24,9 15,3 0,46 0,16 -212 631 -94 077 -588 999 0,35 
70 16,5 11,6 0,45 0,22 -173 847 -100 737 -465 906 0,42 
Me
n 
40 39,3 19,5 0,49 0,10 -172 876 -44 327 -456 838 0,19 
50 29,9 17,0 0,48 0,14 -169 405 -61 445 -445 018 0,26 
60 21,2 13,7 0,47 0,19 -157 727 -76 749 -410 510 0,34 
70 13,4 9,9 0,43 0,23 -131 286 -81 587 -352 875 0,39 
Figure 2 Incremental costs (€) and effects of CCB* compared to no treatment. *CCB = calcium channel blocker.
Table 5 Incremental net health benefit (life years) of
different antihypertensive drugs compared with no
treatment (Costs and life years discounted at 4%)
Men Women
70 60 50 40 70 60 50 40
ACE inhibitor 0,38 0,33 0,25 0,18 0,40 0,33 0,24 0,16
ARB 0,31 0,26 0,19 0,13 0,33 0,27 0,19 0,12
Beta blocker 0,22 0,19 0,14 0,10 0,23 0,19 0,14 0,10
CCB 0,39 0,34 0,26 0,19 0,42 0,35 0,25 0,17
Thiazide 0,37 0,32 0,25 0,18 0,39 0,33 0,24 0,16
*Comparisons were made through CCB, such that all analyses are based on
head-to-head comparisons
**African Americans in the ALLHAT study excluded
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Our analyses are based on meta-analyses from a recent
systematic review [2]. The results are not very different
from other meta-analyses [51,52]. Hence we assume that
our results would not be substantially different if they
were based on other meta-analyses of antihypertensive
drug trials.
In our estimates of lifetime costs (e.g. Table 5), costs
include consumption of all modelled resources. Hence,
it is not possible to read drug prices directly from the
undiscounted column of this table due to the complexity
of NorCaD. This advantage with NorCaD helps avoid
jumping to conclusions that the cheapest drug is the
most cost-effective if no statistically significant evidence
is available. For instance would a small decrease in rates
of myocardial infarction more than outweigh a small
increase in acquisition costs of a cheap generic drug.
Strengths and limitations
The NorCaD model is comprehensive in the sense that it
captures more CVD events and health states than most
previous models. It is also a strength that the model is
based on country-specific data for some of the crucial
input parameters. The NorCaD model is designed primar-
ily for primary prevention strategies for cardiovascular dis-
ease, and is therefore useful not only for statins and other
pharmaceutical interventions, but also non-pharmaceutical
interventions such as dietary advice and exercise.
While several previously published models have esti-
mated the risk of CVD events on the basis of risk equa-
tions (typically the Framingham risk equations), we used
observed incidence rates in the population and adjusted
these rates up or down depending on the presence or
absence of risk factors. The advantage of this approach is
first that we avoid bias introduced by uncertainties in risk
equations, and second that we avoid uncertainties intro-
duced by distance in time or distance in geography. Our
approach, however, is not without problems. Most impor-
tant in this context is that we use register data for inci-
dence rates, and there may be limitations in the quality of
these registers and there may be inconsistencies between
the registries.
The validation process proved that the input to the
model need to be somewhat adjusted to fit Norwegian
mortality data. This is a limitation of the model, which
might be more consistent if it were based on fewer data
sources, such as Framingham data. However, we consid-
ered the use of old data from the US likely to generate
more bias.
Most of the trials that form our evidence base had
duration of less than five years [2]. The life year gain
generated through five years of treatment however is
modest (usually less than 10% of the total gain). For
the time beyond five years, we lack solid empirical
data and simply assume that the relative effect stays
constant. The assumption of “continued benefit” [53]
is not necessarily true, and may overestimate the effect
of treatment.
We have not incorporated side effects into our
model, mainly because we use life years gained as mea-
sure of effectiveness and then possible fatal side effects
will be captured in the clinical trials. The costs of side
effects, however, may not be captured. Thiazide for
example may have diabetogenic effect. Hence, thiazide
may have a smaller effect and higher costs over time
than what is assumed in our analyses. Some side
effects may also have positive impact, such as the
diuretic effect of thiazides. Whether incorporation of
side effects would change the results of these analyses
is uncertain, however. It should be noted, however,
that side effects in terms of mortality is captured in
the model because we used intention-to-treat data
Table 6 Incremental net health benefit (life years) of
various combinations of two antihypertensive drugs
compared to CCB alone(Costs and life years discounted
at 4%)
Men Women
70 60 50 40 70 60 50 40
ACE+beta 0,15 0,13 0,11 0,08 0,15 0,13 0,10 0,07
ACE+CCB 0,26 0,23 0,17 0,12 0,27 0,22 0,16 0,10
ACE+thia 0,25 0,22 0,17 0,12 0,25 0,21 0,15 0,10
ARB+ACE 0,20 0,17 0,12 0,08 0,21 0,16 0,11 0,07
ARB+beta 0,09 0,08 0,06 0,05 0,10 0,09 0,06 0,05
ARB+thia 0,20 0,17 0,13 0,09 0,21 0,17 0,12 0,08
CCB+ARB 0,20 0,17 0,13 0,09 0,22 0,17 0,12 0,08
CCB+beta 0,16 0,14 0,11 0,08 0,17 0,14 0,11 0,08
CCB+thia 0,26 0,23 0,19 0,14 0,27 0,23 0,17 0,12
Thia+bet 0,16 0,14 0,11 0,08 0,16 0,14 0,10 0,07
Table 7 Incremental net health benefit (life-years) of
combinations of three antihypertensive drugs compared
with CCB and thiazide (Costs and life years discounted at
4%)
Men Women
70 60 50 40 70 60 50 40
ARB+Bet+ACE 0,03 0,02 0,02 0,01 0,05 0,04 0,03 0,02
CCB+ARB+ACE 0,11 0,10 0,07 0,05 0,14 0,11 0,08 0,06
CCB+ARB+bet 0,03 0,02 0,01 0,01 0,05 0,04 0,03 0,02
CCB+Bet+ACE 0,08 0,07 0,05 0,04 0,10 0,08 0,06 0,04
Thia+ARB+ACE 0,11 0,10 0,08 0,05 0,13 0,11 0,08 0,05
Thia+ARB+bet 0,02 0,01 0,01 0,00 0,04 0,03 0,02 0,01
Thia+Bet+Ace 0,06 0,06 0,05 0,04 0,07 0,05 0,04 0,03
Thia+CCb+Ace 0,15 0,13 0,11 0,08 0,17 0,14 0,10 0,07
Thia+CCb+Bet 0,10 0,07 0,05 0,02 0,12 0,08 0,05 0,02
Thia+CCB+ARB 0,06 0,06 0,05 0,03 0,07 0,06 0,04 0,03
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from trials. Such side effects are only omitted from the
model if they occur after end of the trials.
As mentioned in the methods section, we assumed a
multiplicative relationship when modelling combination
treatment. Cohort studies have demonstrated an expo-
nential relationship between blood pressure and CVD
mortality. Thus one may argue that the risk reduction is
proportional to the reduction in blood pressure. If one
assumes that one drug results in a given reduction in
blood pressure, independent of level, a combination of
drugs will result in a multiplicative relationship. Even
though some combination trials have been undertaken
[2,54], these are too few to represent a basis for evaluat-
ing all clinical relevant combination therapies. Hence,
the results with respect to combination therapy are
more uncertain than those based with single drug
comparisons.
The idea of a model is mimicking real life. All models
are however to some extent a simplification of the clinical
setting. In this model we chose not to include combina-
tions of health states, such as for instance heart failure
and stroke. In addition, we did not include all possible
cardiovascular events, such as intermittent claudication.
These simplifications would influence results to some
extent, but we regarded the possible gain in accuracy to
not be worth the hassle. This was mainly due to the fact
that trustworthy data on occurrence and progression for
these patients would be difficult to obtain.
Figure 3 Cost-effectiveness acceptability curves based on Monte Carlo simulations of single treatments and no treatment (data on
effectiveness based on head-to-head-trials against CCB in addition to CCB vs placebo) -70 year old men (for simplicity; only curves
with probability higher than 4% included in the graph).
Figure 4 Cost-effectiveness acceptability curves based on Monte Carlo simulations of combination treatments for 70 year old men
(efficacy on heart failure and angina not included) (for simplicity; only curves with probability higher than 3% included in the graph).
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Conclusions
CCB, ARB, thiazide, ACE inhibitor and beta blocker all
represent cost-effective antihypertensives either alone or
in combination. Based on our findings, new clinical
practice guidelines for antihypertensive treatment may
do well in recommending more than one drug class as
first choice.
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